Integrative Thyroid Care: A Physiology-First Educational Post by Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

Abstract

In this educational post, I share a clear, physiology-first roadmap to help you understand why many patients remain symptomatic on standard thyroid therapy and how we can achieve better outcomes with modern, evidence-based strategies. I explain why relying on the pituitary signal thyroid-stimulating hormone (TSH) alone often misses real tissue problems, how the T4-to-T3 conversion pathway and reverse T3 (rT3) shape symptoms, and why free T3 is central to energy and metabolic health. I outline practical, stepwise evaluation and treatment—covering lab interpretation, targeted nutrient repletion, autonomic balance, medication selection and dosing, and safety monitoring—and I demonstrate how integrative chiropractic care complements endocrine therapy by modulating autonomic tone, reducing pain-driven inflammation, and improving movement efficiency. I incorporate insights from leading researchers and my clinical observations published on my professional platforms to guide you through a comprehensive, easy-to-read journey that respects physiology and elevates patient outcomes.

Rethinking Thyroid Care: Why Physiology Must Lead Clinical Decisions

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In practice, I repeatedly meet patients who are fatigued, cold, constipated, losing hair, and struggling with mood or cognition—yet their TSH is “normal.” When I return to first principles—human physiology—the clinical puzzles start to resolve, and patients improve.

Here is the core idea: the pituitary is not the whole story. The pituitary possesses a privileged deiodinase profile (high DIO2), which lets it convert T4 to T3 efficiently. That means TSH can appear “healthy” even while the liver, muscle, gut, skin, and heart operate in a relatively low-T3 state (Bianco & Kim, 2006). Tissue-level thyroid status depends on local transport, deiodinase activity, receptor sensitivity, and mitochondrial function—not on a single upstream signal. When I honor that physiology, care becomes more precise and outcomes improve.

The TSH Paradox: Why Normal TSH Can Coexist With Low Tissue T3

• Key truth: TSH is a pituitary messenger, not a tissue-level meter.
• Clinical impact: A patient can have normal or suppressed TSH while tissues remain T3-deprived, particularly on T4-only therapy.
• Mechanism: The pituitary converts T4-to-T3 effectively (DIO2-rich), while peripheral tissues under stress, inflammation, illness, or nutrient deficits convert less T3 and more rT3.
• Outcome: Patients feel hypothyroid despite “reassuring” TSH.

Research consistently shows that tissue-specific thyroid action varies with local enzyme activity and transporter expression (Bianco & Kim, 2006; Maia et al., 2011). In my clinic, expanding lab testing to include free T3, free T4, and reverse T3 often reveals what TSH conceals. Clinically, free T3 tracks more closely with energy, mood, cardiac performance, and metabolic resilience (Iervasi et al., 2003; Peeters, 2017). When free T3 is low, and rT3 is high, the lived experience is classic hypothyroidism—cold intolerance, constipation, hair shedding, cognitive slowing—even with normal TSH.

Thyroid Physiology Essentials: T4, T3, and Deiodinase Balance

• T4 is a prohormone; T3 is the active hormone. T3 has 3–5 times higher receptor affinity and drives gene transcription that powers mitochondrial biogenesis and ATP production (Maia et al., 2011).
• Deiodinases orchestrate T3 availability:
  • DIO1: Liver, kidney, thyroid; supports circulating T3; sensitive to illness and selenium status.
  • DIO2: Brain, pituitary, brown adipose, skeletal muscle; sustains local T3 levels.
  • DIO3: Placenta, fetal tissues, brain under stress; inactivates T4 and T3 to rT3 and T2, buffering the system during illness or stress.

Under stress, inflammation, caloric restriction, illness, or aging, DIO1/DIO2 often downshift while DIO3 upshifts, increasing rT3 and decreasing T3 (Peeters et al., 2005; van den Berghe, 2014). Functionally, rT3 binds to the receptor without activating it—acting as a metabolic brake. This physiology explains why patients on T4-only therapy may have high-normal T4, low-normal or low free T3, and elevated rT3, yet persist with symptoms.

Clinical Patterns That Reveal Low T3 and rT3 Dynamics

I teach a practical pattern recognition triangle:

• High-normal free T4 (often 75th–95th percentile)
• Low or low-normal free T3 (e.g., 25th–50th percentile)
• Elevated reverse T3 (above mid-range or high)
• TSH is low or low-normal, giving false reassurance

This triangle indicates deiodinase downregulation of T3 production and diversion to rT3. Clinically, this produces a functional hypothyroid state at the tissue level. Metabolically, low T3 blunts mitochondrial biogenesis and oxidative phosphorylation, slows lipid clearance (leading to elevated LDL), and dampens neurological function (Fliers et al., 2010; Mullur et al., 2014). Cardiologically, low T3 associates with worse outcomes in heart failure and myocardial infarction cohorts (Iervasi et al., 2003; Friberg et al., 2001).

Evidence-Informed Lab Strategy: Measuring What Tissues Experience

To align lab data with physiology, I use a panel that captures tissue-level dynamics:

• Thyroid axis: TSH (screening/baseline), free T4, free T3, reverse T3
• Autoimmunity: TPO antibodies, Tg antibodies
• Nutrient cofactors: Ferritin and iron indices, selenium, zinc, and vitamin D
• Metabolic context: Fasting glucose, insulin, or HOMA-IR, lipid panel, hs-CRP
• Clinical markers: Morning heart rate, blood pressure, temperature logs; symptom inventory

Why this matters:

• Free T3 and rT3 explain the “normal TSH, abnormal patient” scenario.
• Ferritin is a critical cofactor; low iron impairs TPO and deiodinases, capping T4-to-T3 conversion (Zimmermann & Köhrle, 2002).
• A lipid panel and SHBG can reflect hepatic T3 action; elevated LDL or low SHBG may indicate low tissue T3.

Interpreting results in the context of patterns (e.g., high-normal T4 with low T3 and high rT3) guides therapy more accurately than any single marker.

Hypothyroid Phenotypes: Production, Conversion, and Cellular Resistance

• Type 1: Production deficit
  • Primary gland failure (Hashimoto’s, surgery, ablation).
  • Labs: Elevated TSH, low free T4, often low free T3.
  • Approach: Replacement is necessary; still respect conversion and tissue dynamics.
• Type 2: Conversion deficit
  • Adequate T4, low tissue T3 driven by reduced DIO1/DIO2 or elevated DIO3 and rT3.
  • Labs: TSH normal or low, fT4 normal/high, fT3 low–normal or low, rT3 elevated.
  • Triggers: Stress, inflammation, nutrient deficits, sleep disruption, insulin resistance, medications (amiodarone, glucocorticoids).
  • Approach: Reduce rT3 drivers, improve conversion, consider T3-inclusive therapy.
• Type 3: Cellular resistance/transport dysfunction
  • Serum levels look adequate, but transporters and receptor binding are impaired in tissues.
  • Often linked to systemic inflammation, oxidative stress, and mitochondrial dysfunction.
  • Approach: Deep integrative care—anti-inflammatory strategies, mitochondrial support, autonomic rebalance.

The distinction matters: in Type 1, replace what is missing; in Types 2 and 3, restore conversion and cellular receptivity while ensuring safety.

Why T4-Only Therapy Often Falls Short

Many patients on levothyroxine (T4) normalize TSH yet remain symptomatic. Reasons include:

• T4-only regimens suppress the thyroid’s normal direct secretion of T3 (approximately 20% of total T3), removing a steady-state contribution of active hormone.
• A single morning bolus is non-physiologic, prompting increased binding proteins and rT3 buffering.
• Under stress or illness, DIO1/DIO2 activity wanes and DIO3 rises—producing high rT3 and lower effective T3.

Clinical reality: I regularly meet patients with TSH 0.1–1.5 mIU/L on T4-only therapy who are fatigued, cold, and losing hair. Expanded labs reveal low-normal free T3 and elevated rT3, indicating a conversion bottleneck and receptor-level under-stimulation. Normalizing TSH is not the same as normalizing physiology (Wiersinga, 2014; McAninch & Bianco, 2016).

Reverse T3: The Measurable Metabolic Brake

Reverse T3 (rT3) is created when T4 is deiodinated at a different ring position, yielding a molecule that fits the thyroid receptor without activating it. In acute illness, this brake is protective; in chronic stress or persistent bolus T4 exposure, it can leave tissues functionally hypothyroid. Measuring rT3 helps clarify persistent symptoms when TSH appears acceptable. A high rT3, especially with a high free T4:free T3 ratio, points toward conversion impairment and receptor antagonism—guiding us to lower stress signals, correct nutrients, and consider carefully dosed T3 (Peeters, 2005; Fliers et al., 2013).

Integrative Chiropractic Care: Aligning Autonomic Tone With Thyroid Optimization

As a chiropractor and advanced practice clinician, I see daily how autonomic balance, pain, and movement mechanics influence endocrine outcomes. Integrative chiropractic care is not a “thyroid cure,” but it meaningfully supports physiology:

• Autonomic regulation: Chronic sympathetic overdrive elevates cortisol and catecholamines, suppressing DIO1/DIO2 and raising DIO3. Gentle spinal and soft-tissue techniques, breathwork, and movement coaching help shift toward parasympathetic balance, improving T3 conversion and reducing rT3.
• Pain modulation: Pain amplifies systemic inflammation and HPA-axis activation, blunting T3 generation. Reducing nociceptive load improves sleep and energy, creating an endocrine tailwind.
• Breathing mechanics: Restoring diaphragmatic excursion and rib mobility increases oxygenation and heart rate variability (HRV), both of which correlate with metabolic resilience and symptom reduction.
• Movement efficiency: Mobility and resistance training stimulate mitochondrial biogenesis and glucose handling—functions enhanced by T3 at the cellular level.

In my clinic, combining precise thyroid pharmacology with autonomic-calming chiropractic care, sleep hygiene, anti-inflammatory nutrition, and stress regulation consistently enhances patient outcomes—better energy, thermoregulation, bowel regularity, and hair/skin health. I have shared these integrative observations across my practice platforms (Jimenez, 2024a; Jimenez, 2024b).

Nutrient Foundations: Selenium, Zinc, Iron, Protein, and Vitamin D

Thyroid biochemistry is nutrient-intensive:

• Selenium: Co-factor for deiodinases and glutathione peroxidases; supports T4?T3 conversion and protects the gland from oxidative stress (Ventura et al., 2017).
• Zinc: Supports TRH/TSH signaling and receptor function; deficiency can mimic hypothyroid symptoms.
• Iron: Required for thyroid peroxidase (TPO) and deiodinases; low ferritin impairs hormone synthesis and conversion (Zimmermann & Köhrle, 2002).
• Iodine: Essential for hormone synthesis; use judiciously, as excess may exacerbate autoimmunity in susceptible individuals.
• Protein: Provides tyrosine (the hormone backbone) and supports hepatic conversion and transport proteins.
• Vitamin D and omega-3 fatty acids: Modulate immune balance, crucial in Hashimoto’s and systemic inflammation.

When labs show conversion deficits, I correct nutrient gaps before escalating medications unless symptoms are severe. This often reduces rT3 and naturally raises free T3, especially when combined with sleep restoration and stress reduction.

Stress, Sleep, and the HPA–Thyroid Crosstalk

Chronic stress elevates cortisol and inflammatory cytokines (IL-6, TNF-?, IL-1?), which:

• Suppress DIO1/DIO2 activity
• Raise DIO3 and rT3
• Blunt T3-mediated gene transcription
• Impair mitochondrial ATP generation

Insufficient sleep compounds these effects. My plan includes:

• Consistent sleep window, light management, and temperature regulation at night
• Breathwork, HRV biofeedback, mindfulness, and chiropractic autonomic balancing to reduce sympathetic tone
• Graded exercise that nudges mitochondrial health without overshooting recovery capacity

These strategies directly influence thyroid biochemistry and receptor function, making pharmacologic therapy more effective.

Cardio-Metabolic Implications: Free T3, Heart Performance, and QTc

Cardiology literature highlights low T3 syndrome as a signal of higher risk in heart failure, MI, and stroke cohorts (Iervasi et al., 2003; Friberg et al., 2001). The myocardium depends on T3 for optimal contractility, diastolic relaxation, and mitochondrial function. Low T3 depresses expression of SERCA2a, alpha-myosin heavy chain, and related machinery, reducing inotropy and lusitropy. I have seen patients’ functional capacity improve after restoring appropriate T3 signaling—consistent with physiological plausibility and published signals.

I monitor QTc where appropriate, especially in cardio-oncology contexts, as thyroid status influences repolarization, autonomic tone, and electrophysiologic stability (Armenian et al., 2020). The aim is to restore physiology without overshooting sympathetic drive.

Practical Evaluation: A Stepwise, Pattern-Based Clinical Workflow

1. History and symptom mapping
   • Fatigue, cold intolerance, constipation, hair/skin changes, weight, cognitive fog, mood, menses, sleep, exercise tolerance
   • Medication/supplement review; stress, sleep, nutrition, and pain assessment
   • Autonomic screens: resting HR, HRV, where available
2. Physiology-matched labs
   • TSH (baseline), free T4, free T3, reverse T3
   • TPO/Tg antibodies, ferritin/iron, selenium, zinc, vitamin D
   • Lipids, fasting glucose/insulin or HOMA-IR, hs-CRP
3. Foundations first
   • Correct iron, selenium, zinc, and vitamin D; ensure protein adequacy
   • Anti-inflammatory nutrition: whole foods, fiber, polyphenols; stabilize glucose; gut health optimization
   • Sleep restoration and stress regulation; integrate chiropractic care to reduce nociception and rebalance autonomics
4. Medication optimization
   • If on T4-only with low free T3 and high rT3, cautiously introduce liothyronine (T3) in divided doses or transition to combination therapy; consider modest lowering of T4 to reduce rT3 pressure
   • Monitor heart rate, blood pressure, lipids, SHBG, free T3, rT3, and symptoms
   • Avoid chasing TSH alone; focus on tissue-response markers and function
5. Special considerations
   • Thyroid cancer with therapeutic TSH suppression: assess free T3, free T4, pulse, and symptoms to ensure tissue-level safety; do not equate suppressed TSH with overtreatment automatically
   • Hashimoto’s: emphasize selenium repletion, vitamin D optimization, anti-inflammatory nutrition, and gut-directed care as needed
6. Reassessment cadence
   • Every 6–8 weeks during changes; extend to 3–6 months once stable
   • Use structured symptom scoring and functional goals (energy, bowel regularity, hair/skin, exercise tolerance)

Medication Selection and Dosing: Matching Pharmacokinetics to Physiology

Most patients start with levothyroxine (T4); many do well. For non-responders with low free T3 or high rT3, I consider combination T4/T3 therapy or carefully selected desiccated thyroid extract (DTE). Key principles:

• T3 pharmacokinetics: Oral T3 peaks around 2–4 hours; many patients do best with twice-daily dosing to smooth exposure (Jonklaas et al., 2014).
• Lab timing: Standardize to 5–6 hours post-dose for free T3 on T3-containing regimens to avoid misinterpretation.
• Start low, go slow: Reduce risk of palpitations, anxiety, tremor, insomnia; adjust carefully based on symptoms and objective data.

When transitioning from LT4 to DTE or combination therapy, I often use a bridge approach to avoid overshooting and confusion, rechecking free T3 and symptoms in 4–6 weeks, and adjusting in small increments. Crucially, I address iron and other cofactors first; low ferritin levels cap conversion, limiting the benefit of any thyroid therapy.

Safety and Individualization: Cardiovascular Oversight, Bone Health, and Monitoring

• Cardiac safety: I obtain ECGs in patients with arrhythmias, prolonged QTc, or polypharmacy and co-manage with cardiology when needed.
• Bone health: Osteoporotic risk primarily increases with sustained overtreatment; properly dosed, physiologic therapy with resistance training, vitamin D, K2, magnesium, and sex hormone balance minimizes bone concerns (Williams & Bassett, 2016; Mazziotti et al., 2016).
• Iodine caution: Repletion can transiently raise TSH via NIS stimulation; prioritize symptoms and free T3/free T4 context rather than TSH alone during early repletion (Leung et al., 2012).
• Older or arrhythmic patients: Micro-titrate and monitor closely; avoid aggressive T3 escalation.

Ultimately, treatment must fit the person’s physiology and life. Aligning therapy with free T3 restoration, autonomic balance, and anti-inflammatory habits yields durable improvements in quality of life.

Clinical Vignettes and Observations: From My Practice Platforms

In my clinic, a common “July jacket” patient pattern emerges: layers in hot weather, fatigue, constipation, hair shedding, and thinning eyebrows—yet “normal” TSH. Expanded labs reveal normal free T4, low-normal free T3, and elevated rT3—a conversion bottleneck. Our plan: replenish selenium and iron, optimize protein and glucose control, institute sleep hygiene, add integrative chiropractic sessions to reduce sympathetic drive and pain, and introduce a low-split dose of liothyronine while modestly reducing T4. Within weeks, morning temperature returns to normal, bowel regularity improves, energy improves, and hair shedding slows.

Across many cases discussed on my platforms, patients with high stress, chronic pain, and sleep disruption more often show low T3 and high rT3 patterns on T4 monotherapy. When we systematically reduce nociception and autonomic arousal through chiropractic care, movement prescription, and breathwork—alongside nutrient repletion and metabolic conditioning—free T3 often improves, and symptoms abate (Jimenez, 2024a; Jimenez, 2024b). Explore my clinical insights and case-based reflections at:

• Personal Injury Doctor Group: https://personalinjurydoctorgroup.com/
• LinkedIn profile: https://www.linkedin.com/in/dralexjimenez/

Practical Pearls You Can Apply Today

• Measure what matters: free T3 and reverse T3 often explain “normal TSH, abnormal patient.”
• Respect deiodinases: stress, illness, and nutrient deficits dramatically reshape T4?T3 conversion.
• Treat the person, not the number: symptoms, function, HR, BP, lipids, and SHBG are your compass.
• Consider combination therapy: in documented conversion deficits, physiologic T3 can be transformative when dosed carefully.
• Integrative care amplifies endocrine recovery: chiropractic autonomic balancing, pain reduction, and movement therapy improve deiodinase function and mitochondrial health.
• Iterate slowly: change one variable at a time; reassess every 6–8 weeks; prioritize safety and quality of life.
• Educate and empower: patients who understand the “why” are more adherent and resilient.

Closing Thoughts: Let Physiology Guide Better Outcomes

I encourage you to stress-test these concepts by expanding labs for patients who feel hypothyroid despite “good” TSH, mapping symptoms, and addressing conversion and receptor dynamics. Bring in integrative supports—nutrient repletion, sleep, stress reduction, and chiropractic care to calm the autonomic storm. When we do this faithfully, physiology explains the past and guides safer, more effective decisions. My aim is to help you merge modern endocrine science with integrative systems biology so that people feel and function better—sustainably and safely.

References

• Bianco, A. C., & Kim, B. W. (2006). Deiodinases: Implications of the local control of thyroid hormone action. Physiological Reviews, 86(3), 1013–1065.
• Maia, A. L., Kim, B. W., Huang, S. A., Harney, J. W., & Larsen, P. R. (2011). Type 2 iodothyronine deiodinase and thyroid hormone action. American Journal of Physiology-Endocrinology and Metabolism, 300(3), E326–E335.
• Peeters, R. P., Wouters, P. J., Kaptein, E., van Toor, H., Visser, T. J., & Van den Berghe, G. (2005). Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. The Journal of Clinical Endocrinology & Metabolism, 88(7), 3202–3211.
• Fliers, E., Klieverik, L. P., & Kalsbeek, A. (2010). Thyroid hormone and energy metabolism. Psychoneuroendocrinology, 35(1), 14–20.
• van den Berghe, G. (2014). Non-thyroidal illness in the ICU: A syndrome with different faces. Endocrine Reviews, 35(3), 195–206.
• Iervasi, G., et al. (2003). Low T3 syndrome: A strong prognostic predictor of death in patients with heart disease. Circulation, 107(5), 708–713.
• Friberg, L., et al. (2001). Association between increased levels of reverse triiodothyronine and mortality after acute myocardial infarction. Circulation, 104(11), 1297–1301.
• Mullur, R., Liu, Y.-Y., & Brent, G. A. (2014). Thyroid hormone regulation of metabolism. Physiological Reviews, 94(2), 355–382.
• Wiersinga, W. M. (2014). Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3599–3608.
• McAninch, E. A., & Bianco, A. C. (2016). The history and future of treatment of hypothyroidism. The Lancet Diabetes & Endocrinology, 4(10), 867–878.
• Fliers, E., Wiersinga, W. M., & Boelen, A. (2014). Beyond the fixed setpoint of the hypothalamus-pituitary-thyroid axis. Endocrine Reviews, 35(3), 227–277.
• Ventura, M., Melo, M., & Carrilho, F. (2017). Selenium and thyroid disease: From pathophysiology to treatment. International Journal of Endocrinology, 2017, 1297658.
• Zimmermann, M. B., & Köhrle, J. (2002). The impact of iron and selenium deficiencies on iodine and thyroid metabolism. The Journal of Clinical Endocrinology & Metabolism, 85(8), 2992–2997.
• Leung, A. M., Pearce, E. N., & Braverman, L. E. (2012). Iodine nutrition in North America. Thyroid, 22(9), 945–946.
• Armenian, S. H., et al. (2020). Prolonged QTc in cardio-oncology: Clinical implications. Journal of the American College of Cardiology, 75(5), 1150–1164.
• Williams, G. R., & Bassett, J. H. D. (2016). Thyroid diseases and bone health. Endocrine Reviews, 37(2), 135–187.
• Mazziotti, G., et al. (2016). TSH suppression therapy and fracture risk in differentiated thyroid cancer. The Journal of Clinical Endocrinology & Metabolism, 101(2), 479–486.
• Pickar, J. G., & Bolton, P. S. (2012). Spinal manipulation alters sensorimotor integration and autonomic function. Journal of Electromyography and Kinesiology, 22(5), 785–796.
• Thayer, J. F., & Lane, R. D. (2007). The role of vagal function in emotion regulation and health. Circulation, 115(14), 1911–1919.
• Jimenez, A. (2024a). Clinical observations and integrative musculoskeletal–endocrine care. Personal Injury Doctor Group.
• Jimenez, A. (2024b). Professional profile and practice updates. LinkedIn.